论文部分内容阅读
目的观察白蛋白结合型紫杉醇治疗晚期乳腺癌的疗效及安全性。方法对39例具有可测量病灶的晚期乳腺癌患者采用白蛋白结合型紫杉醇化疗(90mg/m2),第1、8、15d静脉滴注,用3周,停1周,4周为1周期;单药治疗2个周期以上。所有患者既往均接受过蒽环类药物化疗。结果化疗2个周期后评价疗效,完全缓解2例,部分缓解13例,稳定19例,进展5例,总有效率38.46%。最常见的不良反应为白细胞减少,其次为恶心、呕吐反应和感觉神经病变,Ⅲ度不良反应仅见白细胞减少3例。结论白蛋白结合型紫杉醇治疗晚期乳腺癌疗效较好,且不良反应轻,用药方便,是治疗乳腺癌的理想药物。
Objective To observe the efficacy and safety of albumin-bound paclitaxel in the treatment of advanced breast cancer. Methods Thirty - nine patients with advanced breast cancer with measurable lesions were treated with albumin - bound paclitaxel (90mg / m2), intravenously on the first, the eighth and the fifteenth day for three weeks, one week and four weeks for one cycle. Monotherapy for more than 2 cycles. All patients had received anthracycline chemotherapy. Results After 2 cycles of chemotherapy, the curative effect was evaluated. Complete remission was achieved in 2 cases, partial remission in 13 cases, stable in 19 cases and progression in 5 cases. The total effective rate was 38.46%. The most common adverse reactions were leukopenia, followed by nausea, vomiting and sensory neuropathy, Ⅲ degree adverse reactions only seen in 3 cases of leukopenia. Conclusions Albumin-bound paclitaxel is effective in the treatment of advanced breast cancer and has mild side effects and convenient medication. It is an ideal drug for the treatment of breast cancer.